Writing Recruitment Ads That Clear IRB Review the First Time

Recruitment ad copy is one of the few site deliverables that a reviewer will read word for word and reject over a single adjective. Most rejections aren't about bad intent — they're about phrasing habits borrowed from consumer marketing that don't survive IRB review.

What reviewers are actually checking

IRBs evaluate advertising as an extension of the consent process. The core questions are consistent across boards:

• Is the study clearly identified as research?
• Is the condition or population described without implying a diagnosis or a benefit?
• Are eligibility criteria described accurately, without promising enrollment?
• Is compensation stated factually and without undue emphasis?
• Is there a real contact and a named institution or investigator?

If your draft answers all five plainly, most of the review friction disappears.

The phrases that get flagged

Some patterns come back with edits almost every time:

"New treatment" or "breakthrough therapy." Investigational products aren't treatments until approved. Use "investigational drug" or "study medication."

"Free treatment" or "no-cost care." This suggests therapeutic benefit and implies the study substitutes for medical care. Say what's actually provided: "study-related visits, procedures, and study medication are provided at no cost."

"Earn up to $1,200." Compensation can be mentioned but shouldn't be the headline, bolded, oversized, or the first thing a reader sees. Many boards want it stated as reimbursement for time and travel rather than earnings.

"Do you suffer from…" Emotionally loaded framing draws edits. "Living with" or "diagnosed with" reads cleaner.

"You qualify" or "You're eligible." No one is eligible until screened. Write "you may be able to take part" and always include a screening step.

Efficacy language of any kind. Nothing about improving symptoms, slowing progression, or helping you feel better — even hedged.

A structure that submits cleanly

1. A neutral headline naming the condition and the fact that it's research.
2. One or two sentences on purpose — what's being studied, in plain language.
3. Three to five bullet eligibility items, prefixed with "you may be able to take part if."
4. What participation involves at a high level: number of visits, rough duration.
5. A factual compensation line, if any.
6. Contact information plus the site name and principal investigator.

Practical habits that save review cycles

Submit every variant, not just the master. Character-limited social ad copy, a radio script, a waiting-room flyer, and a landing page headline are separate items in most boards' eyes. Sites commonly get caught when a paid ad platform truncates approved text into something never reviewed.

Screenshot the final rendered version. Approval covers content and presentation. If your platform adds an emoji, a countdown, or a "Learn More" button that changes meaning, capture it.

Build a reusable, pre-approved block library. Keep approved compensation phrasing, PI attribution lines, and "this is a research study" statements in one document so coordinators aren't rewriting from scratch under deadline.

Version and date every asset. When a protocol amendment shifts eligibility, you need to know which ads reference the old criteria and pull them the same day.

Note that translations require separate approval. A certified translation of approved English copy is still new material.

The sites that move fastest through advertising review aren't the ones writing the most persuasive copy. They're the ones whose drafts are boring, accurate, and structurally identical to the last five they submitted.